DEXAMETHASONE SODIUM PHOSPHATE

Post-LOE

Hikma

ANDAINJECTIONINJECTABLE

Approved

Aug 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DEXAMETHASONE SODIUM PHOSPHATE by Hikma is clinical pharmacology dexamethasone sodium phosphate injection has a rapid onset but short duration of action when compared with less soluble preparations. First approved in 2023.

Drug data last refreshed 4h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Dexamethasone sodium phosphate injection has a rapid onset but short duration of action when compared with less soluble preparations. Because of this, it is suitable for the treatment of acute disorders responsive to adrenocortical steroid therapy. Naturally occurring…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT02770807Phase 3Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Started Mar 2017

176 enrolled

Nervous System DiseaseGenetic Syndrome

NCT01255358Phase 2Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Started Feb 2011

22 enrolled

Nervous System DisorderGenetic Syndrome

Worked on DEXAMETHASONE SODIUM PHOSPHATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.